Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Biologic Therapies for Systemic Lupus Erythematosus Treatment: Systematic Review and Meta-Analysis
Helena Hiemisch Lobo Borba, Astrid Wiens, Thaís Teles de Souza, et al.
BioDrugs (2013) Vol. 28, Iss. 2, pp. 211-228
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman, Bryan D. Springer, Gordon Guyatt, et al.
Arthritis Care & Research (2017) Vol. 69, Iss. 8, pp. 1111-1124
Open Access | Times Cited: 178
Systemic lupus erythematosus and ocular involvement: an overview
Rosanna Dammacco
Clinical and Experimental Medicine (2017) Vol. 18, Iss. 2, pp. 135-149
Closed Access | Times Cited: 169
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman, Bryan D. Springer, Gordon Guyatt, et al.
Arthritis & Rheumatology (2017) Vol. 69, Iss. 8, pp. 1538-1551
Open Access | Times Cited: 139
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Joshua S. Davis, David Ferreira, Emma Paige, et al.
Clinical Microbiology Reviews (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 115
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman, Bryan D. Springer, Gordon Guyatt, et al.
The Journal of Arthroplasty (2017) Vol. 32, Iss. 9, pp. 2628-2638
Open Access | Times Cited: 102
Regulating STING in health and disease
Yang Li, Heather L. Wilson, Endre Kiss‐Toth
Journal of Inflammation (2017) Vol. 14, Iss. 1
Open Access | Times Cited: 85
Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis
Meera Ramanujam, Jürgen Steffgen, Sudha Visvanathan, et al.
Autoimmunity Reviews (2020) Vol. 19, Iss. 11, pp. 102668-102668
Open Access | Times Cited: 53
Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
Justin Chan, Giles Walters, Prianka Puri, et al.
BMC Rheumatology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 13
Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome
Magdalena Drożyńska‐Duklas, Anna Kranz, Ilona Zagożdżon, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 1, pp. 239-239
Open Access
Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder
Anwar Fathollahi, N B Gabalou, Saeed Aslani
Lupus (2018) Vol. 27, Iss. 7, pp. 1053-1064
Closed Access | Times Cited: 40
IFN-lambda therapy: current status and future perspectives
Ahmed Lasfar, Andrew Zloza, Karine Cohen-Solal
Drug Discovery Today (2015) Vol. 21, Iss. 1, pp. 167-171
Closed Access | Times Cited: 36
Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses
Jae Il Shin, Han Li, Seoyeon Park, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 2, pp. 343-343
Open Access | Times Cited: 18
Predicting diagnostic gene expression profiles associated with immune infiltration in patients with lupus nephritis
Lin Wang, Zhihua Yang, Hangxing Yu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus
Shiheng Wang, Wanling Ning, Hanqing Tang, et al.
Arthritis Research & Therapy (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus
Rosalie Magro
Therapeutic Advances in Musculoskeletal Disease (2019) Vol. 11
Open Access | Times Cited: 20
Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects
Joshua Chang, Victoria P. Werth
Expert Review of Clinical Immunology (2016) Vol. 12, Iss. 10, pp. 1109-1121
Open Access | Times Cited: 17
Stem cells for lupus nephritis: a concise review of current knowledge
Prenali Dwisthi Sattwika, Rima Mustafa, Ayu Paramaiswari, et al.
Lupus (2018) Vol. 27, Iss. 12, pp. 1881-1897
Closed Access | Times Cited: 17
Stem Cell Therapy as a Treatment for Autoimmune Disease—Updates in Lupus, Scleroderma, and Multiple Sclerosis
Sendhilnathan Ramalingam, Ankoor R. Shah
Current Allergy and Asthma Reports (2021) Vol. 21, Iss. 3
Closed Access | Times Cited: 14
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial
Somnath Bandyopadhyay, Seán Connolly, Omar Jabado, et al.
Lupus Science & Medicine (2017) Vol. 4, Iss. 1, pp. e000206-e000206
Open Access | Times Cited: 13
Update on Biologic Therapies for Systemic Lupus Erythematosus
Helena Hiemisch Lobo Borba, Andreas Funke, Astrid Wiens, et al.
Current Rheumatology Reports (2016) Vol. 18, Iss. 7
Closed Access | Times Cited: 11
Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis
Young Ho Lee, Gwan Gyu Song
Pharmacology (2022) Vol. 108, Iss. 1, pp. 17-26
Open Access | Times Cited: 7
Anti‑CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta‑analysis of randomized controlled trials
Li J, Mingming Wei, Qin Song, et al.
Experimental and Therapeutic Medicine (2019)
Open Access | Times Cited: 10
Interferon Lambda 3/4 (IFNλ3/4) rs12979860 Polymorphisms Is Not Associated With Susceptibility to Systemic Lupus Erythematosus, Although It Regulates OASL Expression in Patients With SLE
Yaneli Juárez-Vicuña, Julia Pérez‐Ramos, Laura Adalid‐Peralta, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 9
Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and meta-analysis of randomised controlled trials
Ying Xu, Jia‐Wen Xu, Yanjiao Wang, et al.
International Immunopharmacology (2022) Vol. 109, pp. 108811-108811
Closed Access | Times Cited: 6
Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis
Shanshan Wu, Yanhai Wang, Jiaojiao Zhang, et al.
African Health Sciences (2020) Vol. 20, Iss. 2, pp. 871-884
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top